REFERENCES
- Ribatti D. The discovery of antiangiogenic molecules: a historical review. Curr Pharm Des. 2009;15:345–352.
- Emerson MV, Lauer AK, Flaxel CJ, et al. Intravitreal bevacizumab (Avastin) treatment of neovascular age-related macular degeneration. Retina. 2007;27:439–444.
- Dafer RM, Schneck M, Friberg TR, Jay WM. Intravitreal ranibizumab and bevacizumab: a review of risk. Semin Ophthalmol. 2007;22:201–204.
- Wu L, Martinez-Castellanos MA, Quiroz-Mercado H, et al. Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol. 2008;246:81–87.
- Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology. 2007;114:855–859.
- Fung AE, Rosenfeld PJ, Reichel E. The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br J Ophthalmol. 2006;90:1344–1349.
- Roth DB, King A, Weiss M, Klein D. Systemic adverse events after bevacizumab. Ophthalmology. 2009;116:1226. e1.
- Park HJ, Guy J. Sixth nerve palsy post intravitreal bevacizumab for AMD: a new possibly causal relationship and complication? Binocul Vis Strabismus Q. 2007;22:209.